Venezuela Clinical Evaluation Scope 2026: Deciding What Is Required

1. Key takeaways

Venezuela requires the submission to include clinical studies conducted by the manufacturer that verify the quality, safety and effectiveness of the characteristics described in the materials or the device, translated into a local language, which may be Spanish or English.

GRZAN’s assessment: defining which products genuinely need clinical material is of more practical value than arguing about how to produce it. Venezuela has not published a graded threshold for clinical data, and in practice submitting clinical material for everything lengthens timelines and inflates cost, while failing to submit it where it is required constitutes a substantive defect. The ability to judge the boundary is scarcer than the ability to compile the file.

The boundary question should therefore be answered in writing at the beginning of the project, not revisited at the end. A short memorandum recording the product category, the available foreign evidence, and the reasoning behind the decision to submit or not to submit clinical material becomes the reference point for the whole file, and it protects the project if the receiving window later takes a different view.

2. Legal basis

Scope statement: the applicable scope and language requirements for clinical study documentation derive from industry comparison material on Latin American medical device registration requirements and are marked as a practical estimate; this verification did not obtain a Venezuelan official reference number that can be cited directly.

3. Expert insights

Insight one: the language requirement accepts either Spanish or English, which is an overlooked practical convenience.

Unlike other Latin American markets that mandate Spanish translation, Venezuela accepts English versions for clinical material. That can save considerable translation cost and time, provided that the receiving window is confirmed to be applying that position at the time of filing. Confirming the position in writing, rather than relying on the general description, is what converts the saving from a hope into a plan.

Insight two: clinical evidence takes many forms and is not limited to clinical trials.

For mature products with a long history of market use, a literature review, a comparison with equivalent products and post-market follow-up data can together form an evidence chain. Venezuela does not require local clinical trials to be conducted, so adapting and reusing data generated abroad is the mainstream route. The work lies in assembling the chain so that each element supports the next, rather than in generating new primary data.

A literature review used in this way needs a defined search scope and a stated inclusion rule. A review that lists publications without saying why they were selected reads as a bibliography, while one that states the population, the device version and the outcomes of interest reads as evidence. The difference costs an afternoon of drafting and changes how the reviewer weighs the material.

Where equivalence is claimed, the file must show it rather than assert it. Technical characteristics, biological characteristics and clinical characteristics each need a comparison, and the differences that remain need an explanation of why they do not affect safety or performance. A comparison table with a blank column for differences is the most common weakness in this type of submission.

Insight three: the boundary for requiring clinical material relates to risk class and to novelty.

High-risk products such as implants and life support devices, and novel products with no equivalent already on the market, need more complete clinical evidence. Low-risk products with an existing equivalent can reduce the requirement through an equivalence argument. The logic matches mainstream international frameworks, but the specific Venezuelan thresholds must be confirmed with the receiving window.

Insight four: clinical material and IVD performance evaluation data are two different sets of evidence.

Therapeutic devices need clinical studies; IVDs need a performance evaluation report, as discussed in the sixteenth article of this series. The two are not interchangeable and are not both required at once; the determining factor is the nature of the product. Misclassifying the evidence type is a more serious error than omitting a document, because it means the file answers a question the reviewer did not ask.

For an IVD, that means the report should address analytical performance and, where relevant, clinical performance in the intended use population, rather than borrowing the structure of a therapeutic clinical evaluation. Reusing a template built for devices that act on the patient produces a document that is long, well formatted and misdirected, which is the least useful combination in a review.

The same distinction decides the language question in practice. Reports written for a stringent jurisdiction can usually be submitted as they stand, because their conclusions are already expressed against the intended use, while internal summaries prepared for another purpose usually need to be rewritten before they can serve as evidence.

4. Practical recommendations

1. Confirm in writing at the document scoping stage whether the product falls within the scope of mandatory clinical material, and keep the confirmation on file.
2. Confirm the language position for clinical material (Spanish or English); where English is accepted, the translation step can be omitted and time saved.
3. Prefer an evidence combination of existing foreign data, an equivalence argument and a literature review, and avoid commissioning new clinical trials.
4. Where the product is already approved in the EU MDR, US FDA or another stringent jurisdiction, adapt the clinical evaluation report, after checking classification differences and adding Venezuela-specific reasoning.

5. Verification checklist

• □ It has been confirmed in writing whether this product falls within the scope of mandatory clinical material
• □ The current language position of the receiving window for clinical material has been confirmed (Spanish or English)
• □ The evidence combination uses foreign data, an equivalence argument and a literature review, without commissioning unnecessary new trials
• □ Existing foreign clinical evaluation reports have been checked for classification differences
• □ For IVD products, it has been confirmed that a performance evaluation report applies rather than clinical study documentation

Regulatory information verified as of October 29, 2026.

For a product-specific feasibility assessment of Venezuela market entry, GRZAN’s regulatory team supports manufacturers, importers and authorized representatives with registration dossiers, conformity documentation and submissions to the Venezuelan health authority. Contact info@grzanglobal.com to discuss your project.